Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026

Cowen maintains a Buy rating on Roivant Sciences Ltd. (ROIV) on March 4, 2026, and keeps the stock as a Top Pick. The ROIV analyst rating was reiterated after Roivant’s TD Cowen presentation and recent legal and regulatory updates. Cowen’s note did not list a new price target. StreetInsider reported the update and the stock moved 6.0% ($1.67) since the note was logged.